Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores

18Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Background: myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic clonal disorders. So, prognostic variables are important to separate patients with a similar biology and clinical outcome. We compared the importance of risk stratification in primary MDS of IPSS and WPSS with the just described revision of IPSS (IPSS-R), and examined if variables obtained by bone marrow immunophenotyping could add prognostic information to any of the scores. Methods: In this prospective study of 101 cases of primary MDS we compared the relation of patients' overall survival with WHO types, IPSS, IPSS-R, WPSS and phenotypic abnormalities of hematopoietic precursors. We examined aberrancies in myelomonocytic precursors and CD34+ cells. Patients were censored when receiving chemotherapy or BM transplantation. Survival analysis was made by Cox regressions and stability of the models was examined by bootstrap resampling. Results: median age: 64 years (15-93). WHO types: 2 cases of 5q-syndrome, 7 of RA, 64 of RCDM and 28 of RAEB. In the univariate Cox analysis, increasing risk category of all scores, degree of anemia, higher percentage of BM blasts, higher number of CD34+ cells and their myeloid fractions besides increasing number of phenotypic abnormalities detected were significantly associated with a shorter survival. In the multivariate analysis comparing the three scores, IPSS-R was the only independent risk factor. Comparing WPSS with phenotypic variables (CD34+/CD13+ cells, CD34+/CD13- cells and "total alterations") the score and "CD34+/CD13+ cells" remained in the model. When IPSS was tested together with these phenotypic variables, only "CD34+/CD13+ cells", and "total alterations" remained in the model. Testing IPSS-R with the phenotypic variables studied, only the score and "CD34+/ CD13+ cells" entered the model. Conclusions: Immunophenotypic analysis of myelomonocytic progenitors provides additional prognostic information to all clinical scores studied. IPSS-R improved risk stratification in MDS compared to the former scores. © 2013 Reis-Alves et al.

Cite

CITATION STYLE

APA

Reis-Alves, S. C., Traina, F., Harada, G., Campos, P. M., Saad, S. T. O., Metze, K., & Lorand-Metze, I. (2013). Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. PLoS ONE, 8(12). https://doi.org/10.1371/journal.pone.0081048

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free